Yesterday Sven Kili, board member and CMO of Swedish company Xintela visited Biostock’s studio. Xintela works within the fields of regenerative medicine and cancer, focusing particularly on cartilage damage and aggressive brain tumours. These are areas where the need for new treatment methods is great and Sven Kili told BioStock more about how Xintela can contribute to this through its patented technology. Kill also discussed Xintela’s studies, the importance of the company’s own GMP facility for production of stem cells as well as upcoming milestones.
Watch the interview with Sven Kili below.
The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.
BioStock.se uses cookies to give you the most relevant experience by remembering your preferences, analyzing website usage and assisting us in our marketing efforts.
By clicking "Accept" you agree to the use of ALL cookies. You can also click on "Cookie settings" to customize your consent.
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
